Zydus Cadila sees 60% of topline from US by FY20 even as rivals lose share

Company has already received highest number of USFDA approvals since April 2017 and aims to launch 75% of these

Cadila Healthcare is having a dream run in the US, riding primarily on growth in base business coupled with a steady pipeline of launches lined up for that country. The contribution of the US in its overall turnover has been growing steadily at a time when most of its peers saw the share of US business shrink in their turnovers -- it grew from 43 per cent in the first quarter of the 2017-18 fiscal to 48 per cent now. The company expects the contribution of US to rise to 60 per cent of its turnover by 2019-20.

This